{"links":{"feed":"https://www.erudio.com/reports/hcrn-gu22-598-nct06809140/feed.json","html":"https://www.erudio.com/reports/hcrn-gu22-598-nct06809140","json":"https://www.erudio.com/reports/hcrn-gu22-598-nct06809140.json","markdown":"https://www.erudio.com/reports/hcrn-gu22-598-nct06809140.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"hcrn-gu22-598-nct06809140"}},"request":"https://www.erudio.com/contact?report=hcrn-gu22-598-nct06809140"},"offer":{"cited_clinicians":14,"cited_commentary_sources":11,"verified_hcp_statements":173,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":20},"for_sale":true,"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"hcrn-gu22-598-nct06809140"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=hcrn-gu22-598-nct06809140","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/hcrn-gu22-598-nct06809140","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 173 verified statements · 87 from 14 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-17T23:44:40.719475Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC"},{"claim_count":10,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":14,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":15,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":24,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":27,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":19,"coverage":"discussed","id":"A1","source_count":4,"title":"ctDNA, utDNA and multimodal selection for bladder preservation"},{"claim_count":44,"coverage":"discussed","id":"A2","source_count":3,"title":"Systemic-treatment duration and the contribution of postoperative therapy"},{"claim_count":13,"coverage":"discussed","id":"A3","source_count":3,"title":"Patient priorities, quality of life and the burden of retaining the bladder"},{"claim_count":16,"coverage":"discussed","id":"A4","source_count":5,"title":"Routine-care adoption, informed consent and prospective evidence"}],"counts":{"beyond_population_findings":4,"beyond_population_statements":28,"cited_clinicians":14,"cited_clinicians_by_role":{"physician":8,"physician, Medical oncology":3,"physician, Radiation oncology":1,"physician, Surgical oncology":1,"physician, Urology":1},"cited_physicians":14,"cited_sources":12,"claims_by_expression_type":{"comparison":6,"experience":10,"interpretation":27,"opinion":59,"primary_context":2,"question":23,"restatement":21,"uncertainty":16,"unspecified":9},"claims_by_kind":{"protocol_statement":2,"source_observation":171},"clinician_statements":87,"evidence_units":166,"findings":13,"organisational_accounts":1,"people_cited":22,"people_identity_verified":20,"people_total":22,"screened_sources":20,"verified_claims":173},"findings_index":[{"cited_clinicians":4,"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":4,"views":6},"limitations":3,"links":{"context":0,"support":18},"ma_question":true,"named_voices":5,"passages":17,"sources":6,"sources_by_kind":{"commentary":4,"media":1,"registry":1}},"title":"Clinical complete response: why some clinicians question its use alone to omit cystectomy","title_holders":{"cited_claim_ids":["claim-0b83e0c514c22f13f6a6","claim-feb11ba328c965773d35","claim-935dff124175882476b9","claim-fc5e046e49458683895e","claim-690e1a1e3bf46d0675f6"],"clinicians":true,"holders":2,"speakers":5,"view":"reading"},"evidence_line":"14 statements from 5 speakers in 6 sources, 1 of them a podcast or video","holder_line":"2 of the 5 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":5,"id":"F2","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":1,"questions":3,"restated":3,"views":9},"limitations":3,"links":{"context":2,"support":18},"ma_question":true,"named_voices":7,"passages":14,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"registry":1}},"title":"Complete response: why some speakers ask if it proves durable local control and cure","title_holders":{"cited_claim_ids":["claim-b89a457f0253532ca5e7","claim-c7b223e43536c55dad19","claim-31718ad8382231a1c63c"],"clinicians":false,"holders":3,"speakers":7,"view":"reading"},"evidence_line":"16 statements from 7 speakers in 5 sources, 1 of them a podcast or video","holder_line":"3 of the 7 named speakers in this finding hold this view"},{"cited_clinicians":7,"id":"F3","structure":{"claims":20,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":1,"views":17},"limitations":3,"links":{"context":3,"support":22},"ma_question":true,"named_voices":9,"passages":17,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Bladder sparing: where speakers split on fixed versus response-adapted duration","title_holders":{"cited_claim_ids":["claim-fd1b8407d9705ed1cfef","claim-759dda5ccf09c59835b9","claim-3d70c3cc7b0c8f06a680","claim-6f123c086e60b60a6eaa","claim-1466c0cf42909c82a2b7","claim-7dbd8064c15bd7909fc7","claim-57254672d621ceaa2ec4","claim-01662af8bb58e2ccb478","claim-dcbb53c0b795b43a8eba","claim-56baee7daf17e21d0251","claim-18c6ab94f07386e996f2","claim-d7a786ef928539e9e8f5","claim-7645dbc89ddd0c74e38b","claim-54eca439ed074ff09c73","claim-de193b23e48bce59dffc"],"clinicians":false,"holders":9,"sides":[{"cited_claim_ids":["claim-fd1b8407d9705ed1cfef","claim-759dda5ccf09c59835b9","claim-3d70c3cc7b0c8f06a680","claim-6f123c086e60b60a6eaa","claim-1466c0cf42909c82a2b7"],"holders":1},{"cited_claim_ids":["claim-7dbd8064c15bd7909fc7","claim-57254672d621ceaa2ec4","claim-01662af8bb58e2ccb478","claim-dcbb53c0b795b43a8eba","claim-56baee7daf17e21d0251","claim-18c6ab94f07386e996f2","claim-d7a786ef928539e9e8f5","claim-7645dbc89ddd0c74e38b","claim-54eca439ed074ff09c73","claim-de193b23e48bce59dffc"],"holders":8}],"speakers":9,"view":"split"},"evidence_line":"20 statements from 9 speakers in 2 sources, 1 of them a podcast or video","holder_line":"9 of the 9 named speakers in this finding take a side on this question: 1 on one side, 8 on the other"},{"cited_clinicians":7,"id":"F4","structure":{"claims":27,"claims_by_group":{"comparisons":1,"experience":3,"questions":8,"restated":8,"views":7},"limitations":4,"links":{"context":1,"support":31},"ma_question":true,"named_voices":7,"passages":23,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Bladder sparing: what most clinicians highlight about toxicity with prolonged treatment","title_holders":{"cited_claim_ids":["claim-7498100d31ede38f6752","claim-bf748b21c5b91076e54f","claim-484446ef2c9910608482","claim-bf20fe6a4568cb99ffa2","claim-93639f84d85c535e443e","claim-9e91ea19003feb44177c","claim-9faefcf5691044d8f548","claim-9e0ab506248e5b26a3fd","claim-de0bd4e3dd175fc42116","claim-5a7b30d1c11d27f1ffb3","claim-ad7c98954432f76bb90b","claim-14f00c501aaaec829c5b","claim-53d86716e0be0f545ac8","claim-891bb41226c3bf432105","claim-6050ed4ccbac9125f284","claim-54eca439ed074ff09c73","claim-e5d212ba8702ca7eba20","claim-27c02f2e34610285da70"],"clinicians":true,"holders":6,"speakers":7,"view":"reading"},"evidence_line":"27 statements from 7 speakers in 4 sources, 1 of them a podcast or video","holder_line":"6 of the 7 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":6,"id":"F5","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":6,"restated":0,"views":10},"limitations":3,"links":{"context":2,"support":18},"ma_question":true,"named_voices":7,"passages":16,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"CtDNA/utDNA: most speakers question readiness, but some propose guided care","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-6050ed4ccbac9125f284","claim-d7a786ef928539e9e8f5","claim-62f7bf0b6d8521ddfb13"],"clause":"some propose guided care","holders":3},"cited_claim_ids":["claim-b2d9efaa06090b0c55d1","claim-ba635d974bd086a08499","claim-2cdbc89600e5e2f8978a","claim-edf04ca20148d2f32257","claim-6050ed4ccbac9125f284","claim-856743fa51097c267661","claim-c7f5c046e675b30ba95d","claim-b3356003724d1dfe5a84"],"clinicians":false,"holders":4,"speakers":7,"view":"reading"},"evidence_line":"16 statements from 7 speakers in 3 sources, 1 of them a podcast or video","holder_line":"4 of the 7 named speakers in this finding hold this view; 3 of the 7 hold its caveat, “some propose guided care”"},{"cited_clinicians":3,"id":"F6","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":5,"views":12},"limitations":4,"links":{"context":1,"support":26},"ma_question":true,"named_voices":5,"passages":24,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"registry":1}},"title":"Surgery omission: most speakers value trials, but most note a trial's limits","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-715199218cbfe88d365b","claim-759dda5ccf09c59835b9","claim-3f5a1f2c6d588b509929","claim-763e72c60188fd7a2009","claim-972bd46ad5a869220183","claim-faa7c918fd6f3c03a45e","claim-dcbb53c0b795b43a8eba","claim-1160158be7c078639501"],"clause":"most note a trial's limits","holders":4},"cited_claim_ids":["claim-759dda5ccf09c59835b9","claim-3f5a1f2c6d588b509929","claim-faa7c918fd6f3c03a45e","claim-9bc6dc0add9f706cfe8c","claim-1160158be7c078639501","claim-d52b624dff07bde274ad"],"clinicians":false,"holders":4,"speakers":5,"view":"reading"},"evidence_line":"21 statements from 5 speakers in 3 sources, 1 of them a podcast or video","holder_line":"4 of the 5 named speakers in this finding hold this view; 4 of the 5 hold its caveat, “most note a trial's limits”"},{"cited_clinicians":6,"id":"F9","structure":{"claims":25,"claims_by_group":{"comparisons":0,"experience":3,"questions":5,"restated":2,"views":15},"limitations":3,"links":{"context":2,"support":28},"ma_question":true,"named_voices":9,"passages":26,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Bladder preservation: what speakers say","evidence_line":"25 statements from 9 speakers in 4 sources, 1 of them a podcast or video"},{"cited_clinicians":3,"id":"F10","structure":{"claims":24,"claims_by_group":{"comparisons":1,"experience":0,"questions":8,"restated":4,"views":11},"limitations":5,"links":{"context":7,"support":33},"ma_question":true,"named_voices":4,"passages":32,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"VOLGA: where speakers split on using future duration data across regimens","title_holders":{"cited_claim_ids":["claim-9b32b6fa67d82d196205","claim-682b385aca7b197c56dd","claim-c621645497b8e2bb283b","claim-985af361d174af5cb63c","claim-96beedb250a9e9855907","claim-d03156dcbf8ccb0b0639","claim-da81ed09f7ca35265402","claim-2da63745d50590b14093","claim-faa7c918fd6f3c03a45e","claim-e5d212ba8702ca7eba20","claim-76e42c0ce6a7d3864b88"],"clinicians":false,"holders":4,"sides":[{"cited_claim_ids":["claim-9b32b6fa67d82d196205","claim-682b385aca7b197c56dd","claim-c621645497b8e2bb283b","claim-985af361d174af5cb63c","claim-96beedb250a9e9855907","claim-d03156dcbf8ccb0b0639","claim-da81ed09f7ca35265402","claim-2da63745d50590b14093","claim-faa7c918fd6f3c03a45e","claim-e5d212ba8702ca7eba20"],"holders":3},{"cited_claim_ids":["claim-76e42c0ce6a7d3864b88"],"holders":1}],"speakers":4,"view":"split"},"evidence_line":"24 statements from 4 speakers in 3 sources, 1 of them a podcast or video","holder_line":"4 of the 4 named speakers in this finding take a side on this question: 3 on one side, 1 on the other"},{"cited_clinicians":2,"id":"F13","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":0,"views":6},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":3,"passages":5,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Perioperative MIBC: why speakers favor more individualized treatment","title_holders":{"cited_claim_ids":["claim-7375b7898ae632224108","claim-00f3f36906bba3f12e5e","claim-56baee7daf17e21d0251","claim-976e68590e5aaa045123","claim-579481f5d13b54b31174","claim-ed68e6e77b64a295a03b","claim-69049d9ec24eed953466"],"clinicians":false,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"9 statements from 3 speakers in 4 sources, 1 of them a podcast or video","holder_line":"3 of the 3 named speakers in this finding hold this view"},{"cited_clinicians":3,"id":"F7","population":"beyond","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":4,"views":4},"limitations":4,"links":{"context":3,"support":16},"ma_question":true,"named_voices":3,"passages":13,"sources":2,"sources_by_kind":{"media":1,"registry":1}},"title":"Radiation and salvage: where clinicians split on local treatment after clinical CR","title_holders":{"cited_claim_ids":["claim-7bd9501d90de1b3dc5e7","claim-852ea31cf749985b9203","claim-d4e1f5fbe6d7aac2e0f3","claim-abd92d01f076058a83e2","claim-e25b06922938c2737344"],"clinicians":true,"holders":2,"sides":[{"cited_claim_ids":["claim-7bd9501d90de1b3dc5e7","claim-852ea31cf749985b9203","claim-d4e1f5fbe6d7aac2e0f3"],"holders":1},{"cited_claim_ids":["claim-abd92d01f076058a83e2","claim-e25b06922938c2737344"],"holders":1}],"speakers":3,"view":"split"},"evidence_line":"11 statements from 3 speakers in 2 sources, 1 of them a podcast or video","holder_line":"2 of the 3 named speakers in this finding take a side on this question: 1 on one side, 1 on the other; every named speaker in this finding is a confirmed clinician"},{"cited_clinicians":2,"id":"F8","population":"beyond","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":4},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":3,"passages":7,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"After clinical CR: which options most speakers would test for bladder sparing","title_holders":{"cited_claim_ids":["claim-915036b1fc54cbe040ba","claim-944a7f1cb07bb4b33bce","claim-0cfc1d6557f70889d0c8","claim-56baee7daf17e21d0251"],"clinicians":false,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"6 statements from 3 speakers in 2 sources, 1 of them a podcast or video","holder_line":"2 of the 3 named speakers in this finding hold this view"},{"cited_clinicians":3,"id":"F11","population":"beyond","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":3,"views":5},"limitations":3,"links":{"context":1,"support":14},"ma_question":true,"named_voices":4,"passages":13,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"T4 response: some clinicians question clinical CR; a speaker proposes stage limits","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-55ea4708ebeacc848635","claim-d7da09d911deae6ed8b8","claim-619fec16e67a80f137e8"],"clause":"a speaker proposes stage limits","holders":1},"cited_claim_ids":["claim-39e6c9e9273f77bc7b42","claim-1fa578f98b6a77663b86","claim-1e25e7d65e195eb3e0ac","claim-dcfd0512ce64701b93dd","claim-817f8f78ffdbce5a560e"],"clinicians":true,"holders":2,"speakers":4,"view":"reading"},"evidence_line":"11 statements from 4 speakers in 2 sources, 1 of them a podcast or video","holder_line":"2 of the 4 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 4 holds its caveat, “a speaker proposes stage limits”"},{"cited_clinicians":3,"id":"F12","population":"beyond","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":5,"views":5},"limitations":4,"links":{"context":4,"support":11},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Bladder sparing: how speakers use earlier and metastatic studies as context","title_holders":{"cited_claim_ids":["claim-ea148c51d3dd6061041f","claim-a455a7c48ea4129cd3ab","claim-a7af5980fd4526a108ba","claim-0155f7f236a261166371","claim-d5981af06e6fce0eb70b","claim-feeedefd95f33ba1a284","claim-74dfd4018935f0e143bc","claim-faa7c918fd6f3c03a45e"],"clinicians":false,"holders":4,"speakers":4,"view":"reading"},"evidence_line":"11 statements from 4 speakers in 5 sources, 1 of them a podcast or video","holder_line":"4 of the 4 named speakers in this finding hold this view"}],"open_question":{"basis":"From finding F1 (14 statements from 5 speakers in 6 sources)","cited_claim_ids":["claim-c99d2fb84015daebe0fe","claim-451df09e7466a39d717a","claim-0b83e0c514c22f13f6a6","claim-feb11ba328c965773d35","claim-935dff124175882476b9","claim-3233b9784a62e278bc13","claim-4f7b586b369d541add00","claim-902d4ea5aaebbd96fb9a","claim-972bd46ad5a869220183","claim-fc5e046e49458683895e","claim-c7f5c046e675b30ba95d","claim-4802b491fdf3f4efec56","claim-690e1a1e3bf46d0675f6"],"finding_ids":["F1"],"question":"What evidence linking clinical to pathological complete response do clinicians need before clinical complete response can guide cystectomy omission after enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers question whether clinical complete response is sufficient to omit cystectomy"},{"id":"section-2","level":2,"title":"Speakers and X accounts distinguish metastatic prognosis from durable local control and preservation of cure"},{"id":"section-3","level":2,"title":"Speakers and X accounts debate fixed nine-cycle EVP versus earlier response-adapted decisions"},{"id":"section-4","level":2,"title":"Speakers and X accounts ask for exposure-specific safety data before equating bladder preservation with better quality of life"},{"id":"section-5","level":2,"title":"Whether ctDNA and utDNA can guide bladder preservation rather than remain exploratory"},{"id":"section-6","level":2,"title":"Speakers value prospective studies but differ over what a single-arm surgery-omission study can establish"},{"id":"section-7","level":2,"title":"Speakers welcome bladder preservation but warn that routine practice may precede evidence"},{"id":"section-8","level":2,"title":"Speakers see VOLGA as informative for duration, not an automatic answer for EV–pembrolizumab"},{"id":"section-9","level":2,"title":"One speaker highlights poor responders; one X account proposes biology-based regimen selection"},{"id":"section-10","level":2,"title":"Beyond the trial population"},{"id":"section-11","level":3,"title":"Speakers debate radiation after clinical complete response and its implications for later salvage"},{"id":"section-12","level":3,"title":"X accounts propose bladder-directed or less intensive alternatives after EVP response"},{"id":"section-13","level":3,"title":"One X account proposes stage restrictions; speakers question response assessment after T4 downstaging"},{"id":"section-14","level":3,"title":"Whether earlier bladder-sparing and metastatic observations translate to EVP-based selective preservation"},{"id":"section-15","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":10},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":3},{"id":"F9","shared_claims":1}],"id":"T1","label":"Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":9},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":2},{"id":"F9","shared_claims":5}],"id":"T2","label":"Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response"},{"findings":[{"id":"F2","shared_claims":7},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F9","shared_claims":4},{"id":"F10","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F10","shared_claims":1},{"id":"F13","shared_claims":5}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F6","shared_claims":5},{"id":"F9","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":23},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F6","shared_claims":16},{"id":"F9","shared_claims":5},{"id":"F10","shared_claims":3},{"id":"F13","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-17T23:44:40.719475Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-18T05:36:09Z","record_hash":"ee8a7bd1df2a1350a01308071dac4ee836bd852b2bda1aa70e24a05e3b3cf1aa","release_hash":"8b04816ef3cb2e1ec8f83963ca119838b152e7a6c567485a2464b13a2f450f44","report_id":"erudio-nct06809140","run_id":"52c021e0-13fe-4311-ae0e-e6eb652880ed","schema_version":"5.0","slug":"hcrn-gu22-598-nct06809140","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited distinguish HCRN GU22-598 by its stringent biopsy assessment, qualifying broader concern that apparent clearance may conceal cancer. Much of the debate concerns EV209: one physician supports maintaining planned EV–pembrolizumab exposure to isolate the effect of omitting surgery, while another favors earlier stopping for exceptional responders because of neuropathy risk. No target-trial outcomes are reported in the sources reviewed for this edition.","examples":[],"meta_description":"20 sources screened · 173 verified statements (87 from clinicians verified by NPI or staff page) from 12 sources · 13 findings. Updated Nov 17, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-18T05:36:09Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":20},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a question about current treatment perspectives on selective bladder sparing in muscle-invasive bladder cancer; a view on response assessment and treatment duration when considering bladder sparing after systemic therapy for muscle-invasive bladder cancer; a question about the lack of comparative evidence for selective bladder sparing with systemic treatment; a remark on the provenance of relayed commentary about bladder-sparing treatment for muscle-invasive bladder cancer; a view on the practical ease of administering EV–pembrolizumab versus platinum chemotherapy; a view on the relative administration burden of enfortumab vedotin plus pembrolizumab versus platinum chemotherapy.","22 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 39 sources about other trials or topics are not included.","The sources reviewed for this edition contain registry methods and commentary, not an outcome report for NCT06809140. No target-trial efficacy, safety or equivalence conclusion can be drawn from these views.","The most detailed debate concerns the separate EV209 study. Its 240-patient descriptions, treatment-assessment schedule and methodological defenses must not be treated as the target protocol.","Some episode passages cannot be attributed to a named speaker. Guest lists and recurring transcript labels do not resolve who said those passages.","The sources are not a representative sample of HCPs. Source totals, reposts, parallel-language accounts and repeated appearances by the same people do not establish prevalence, independence or consensus.","Several figures were recalled approximately, questioned or used hypothetically. In particular, treatment-completion and mortality exchanges do not establish reliable exposure-specific death rates.","Earlier-study results, metastatic observations, alternative regimens and proposed biomarker-defined strategies remain attributed context; they do not become results or validated selection rules for this trial.","The discussion uses EV209 or EV-209, and one reply uses EV208. These descriptions concern a separate surgery-omission study and must not be merged with the target HCRN GU22-598 protocol."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":10,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":11,"methods":1},"count":12,"evidence_window":{"end":"2026-11-14","start":"2025-06-27"},"retrieval_snapshot":"2026-11-17T17:38:12.090272Z","timeline":[{"count":2,"week":"2025-W26"},{"count":2,"week":"2026-W09"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W41"},{"count":2,"week":"2026-W46"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06809140:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06809140:context","quote_policy":"short_quote_link_out"},{"id":"openfda:b5631d3e-4604-4363-8f20-11dfc5a4a8ed:20260804","quote_policy":"short_quote_link_out"},{"id":"openfda:9333c79b-d487-4538-a9f0-71b91a02b287:20261016","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e1bb19","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938584717164498967:19e12243-fd77-4fe1-8c53-e9c92a78cdc4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1938585232371765322:96ecc998-89ba-4bfa-a714-53ed6ff101ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027066393485594682:1ec49ee8-398c-4a57-8b51-d2c89fc8bf94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027426602901217482:4b108ba5-6b80-4cc1-b72f-73fd7d67b927","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027543740064436353:696b4a6a-4808-46d0-9166-f952f6bdb94b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027544670914678996:381fa600-6ecc-402c-b2c2-832cff38123e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2035367679490413024:50b4403d-ed12-437b-aa16-a8c56791a6ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2042101235109556400:5afc67c1-ceee-467e-a33c-dfecc8df2f7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055666635894108506:9065c742-af22-4c8e-bc06-e68dbba9b0ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055667471294537945:4be76e54-6606-4181-a325-e911346b8a38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2075660252830118051:20bc5593-614c-40d4-aee6-78638e0c357c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107922478496436356:6d6542ea-5113-4033-81b5-e9419a93fcc0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121345921455661410:13f2d478-0ac4-4bd7-8b3e-a1412cca89d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121346877761212429:677b1aa2-9c9f-4cfe-8b47-5181def7b260","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121346897810186529:832cb704-c973-44be-bada-ea6a3cc7563e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121347372005708154:d6887a70-d7b1-44fc-af74-e19ffeb0f9cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121363214667530399:68ca3aca-47a3-42ae-b674-73b07f367778","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121612696428699926:f470cebc-5e04-41b0-8a47-6bd0720707ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121692765754982818:c747992b-d0f9-41fe-bd7d-e2578436e8fc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":19,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":20},"count":20,"evidence_window":{"end":"2026-11-14","start":"2025-06-27"},"retrieval_snapshot":"2026-11-17T17:38:12.090272Z","timeline":[{"count":2,"week":"2025-W26"},{"count":4,"week":"2026-W09"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W15"},{"count":2,"week":"2026-W20"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W41"},{"count":7,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":111,"publication":0,"registry":2,"regulatory":0,"x_thread":60,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Padcev"],"label":"enfortumab vedotin","slug":"enfortumab-vedotin"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"reason":"Unmapped registry condition: Muscle Invasive Bladder Urothelial Carcinoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Urothelial carcinoma","slug":"urothelial-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"HCRN GU22-598","aliases":["HCRN GU22-598","HCRN-GU22-598","Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer","Phase 2 Trial of Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Urothelial Cancer of the Bladder"],"brief_title":"Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer","collaborators":["Seagen Inc.","Astellas Pharma Inc","Merck Sharp & Dohme LLC","Icahn School of Medicine at Mount Sinai"],"conditions":["Muscle Invasive Bladder Urothelial Carcinoma"],"display_condition":"muscle-invasive urothelial cancer of the bladder","display_interventions":[["enfortumab vedotin","pembrolizumab"]],"enrollment":{"count":75,"type":"ESTIMATED"},"interventions":[{"name":"Enfortumab vedotin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06809140","official_title":"Phase 2 Trial of Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Urothelial Cancer of the Bladder","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2027-11","type":"ESTIMATED"},"primary_endpoints":[{"description":"Clinical complete response rate will be defined as cT0 or cTa (low grade) disease at the time of restaging after 3 cycles of induction enfortumab vedotin plus pembrolizumab","measure":"Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC","timeFrame":"9 weeks"},{"description":"Estimate the 2-year bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response","measure":"Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response","timeFrame":"2 years"}],"registered_date":{"date":"2025-02-05","type":"ACTUAL"},"registry_last_updated":"2026-08-05","registry_url":"https://clinicaltrials.gov/study/NCT06809140","short_name":"HCRN GU22-598","short_name_basis":"canonical_name","sponsor":"Matthew Galsky","start_date":{"date":"2025-04-07","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"HCRN-GU22-598","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}